Improved Renal Function after Five Years of Growth Hormone (GH) Therapy in GH-Deficient (GHD) Adult Survivors of Childhood Leukemia

2011 ◽  
pp. P2-366-P2-366
Author(s):  
Cecilia Follin ◽  
Thomas Wiebe ◽  
Christian Moell ◽  
Eva Marie Erfurth
Keyword(s):  
Growth Hormone ◽  
Renal Function ◽  
Childhood Leukemia ◽  
Adult Survivors ◽  
Gh Therapy

Issues in the Transition From Childhood to Adult Growth Hormone Therapy

PEDIATRICS ◽  
1999 ◽  
Vol 104 (Supplement_5) ◽  
pp. 1004-1010
Author(s):  
David B. Allen
Keyword(s):  
Growth Hormone ◽  
Replacement Therapy ◽  
Blood Lipid ◽  
Hormone Deficiency ◽  
Late Adolescent ◽  
Gh Therapy ◽  
Gh Treatment ◽  
Beneficial Effects ◽  
Gh Replacement ◽  
Adult Growth

The consequences of severe growth hormone deficiency (GHD) in adults and the beneficial effects of GH replacement therapy are clear. However, the majority of children who have a diagnosis of GHD and who are treated with GH do not have permanent GHD and will not require treatment during adulthood. Several issues must be considered in selecting candidates for adult GH treatment and transitioning their care from pediatrics to adult medicine. Counseling about possible lifelong treatment should focus on children with panhypopituitarism and those with severe isolated GHD that is associated with central nervous system abnormalities. When to terminate growth-promoting GH therapy should be guided by balancing the high cost of late-adolescent treatment with the attainment of reasonable statural goals. Retesting for GH secretion is appropriate for all candidates for adult GH therapy; the GH axis can be tested within weeks after the cessation of treatment, but confirming an emerging adult GHD state with body composition, blood lipid, and quality-of-life assessments may require 1 year or more of observation. Selecting patients for lifelong adult GH replacement therapy will present diagnostic, therapeutic, and ethical problems similar to those in treating childhood GHD. The experience and expertise of pediatric endocrinologists in diagnosing and treating GHD should be offered and used in identifying and transitioning appropriate patients to adult GH therapy.

scholarly journals Chiari type 1 malformation associated with central sleep apnea after high dose growth hormone (GH) therapy in a 12-year-old boy: A case report

2018 ◽  
Vol 27 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Toshihiko Mori ◽  
Eri Nishino ◽  
Tomomi Jitsukawa ◽  
Emiko Hoshino ◽  
Satoshi Hirakawa ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Sleep Apnea ◽  
Central Sleep Apnea ◽  
High Dose ◽  
Gh Therapy ◽  
Chiari Type ◽  
Chiari Type 1 Malformation

scholarly journals Blood asymmetric dimethylarginine and nitrite/nitrate concentrations in short-stature children born small for gestational age with and without growth hormone therapy

2017 ◽  
Vol 46 (2) ◽  
pp. 761-772 ◽  
Author(s):  
Hironori Nagasaka ◽  
Ichiro Morioka ◽  
Mayuko Takuwa ◽  
Mariko Nakacho ◽  
Mayumi Yoshida ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Growth Hormone ◽  
Asymmetric Dimethylarginine ◽  
Therapy Group ◽  
Adma Level ◽  
Gh Therapy ◽  
Normal Children ◽  
Group A ◽  
Group B ◽  
Nitrite Nitrate

Objective To investigate the basal amino acid metabolism and impact of growth hormone (GH) therapy in short-stature children born small for gestational age (short SGA children). Methods In this age-matched case-control study, the basal blood levels of amino acids, asymmetric dimethylarginine (ADMA), and nitrite/nitrate (NOx) were compared between 24 short SGA children and 25 age-matched normal children. Changes in these parameters were assessed for 12 months in 12 short SGA children initiating GH therapy (Group A) and 12 age-matched short SGA children without GH therapy (Group B). Results The arginine levels were significantly lower in the short SGA than in normal children. The ADMA levels were significantly higher and NOx levels were significantly lower in the short SGA than normal children. In Group A, the ADMA level was significantly lower and NOx level was significantly higher at 6 months than at baseline. At 12 months, the ADMA level in Group A began to increase, but the NOx level remained the same. Group B showed no significant changes. Conclusions This study is the first to show that ADMA is promoted and nitric oxide is suppressed in short SGA children and that GH therapy affects the production of ADMA and nitric oxide.

The influence of growth hormone (GH) therapy on cardiac performance in patients with childhood onset GH deficiency

2005 ◽  
Vol 15 (2) ◽  
pp. 156-164 ◽  
Author(s):  
A. Minczykowski ◽  
M. Gryczynska ◽  
K. Ziemnicka ◽  
R. Czepczynski ◽  
J. Sowinski ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Gh Deficiency ◽  
Cardiac Performance ◽  
Childhood Onset ◽  
Gh Therapy

scholarly journals Provincial Disparities of Growth Hormone Coverage for Young Adult Survivors of Paediatric Brain Tumours across Canada

2014 ◽  
Vol 9 (3) ◽  
pp. 80-96
Author(s):  
Haroon Hasan ◽  
Fuchsia Howard ◽  
Steven Morgan ◽  
Daniel Metzger ◽  
Andrea Lo ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Young Adult ◽  
Brain Tumours ◽  
Adult Survivors ◽  
Young Adult Survivors ◽  
Paediatric Brain Tumours

Effects of growth hormone and IGF-I on renal function in rats with normal and reduced renal mass

1990 ◽  
Vol 259 (5) ◽  
pp. F747-F751 ◽  
Author(s):  
S. B. Miller ◽  
V. A. Hansen ◽  
M. R. Hammerman
Keyword(s):  
Growth Hormone ◽  
Renal Function ◽  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Renal Mass ◽  
Filtration Rate ◽  
Inulin Clearance ◽  
Mass Reduction ◽  
Contralateral Kidney ◽  
Igf I

To characterize actions of growth hormone (GH) and insulin-like growth factor ( (IGF-I) on renal function in rats with normal and reduced renal mass, we administered recombinant bovine growth hormone (bGH) or human IGF-I (hIGF-I) to normal rats or to rats that had undergone unilateral nephrectomy and two-thirds infarction of the contralateral kidney, and measured inulin and p-aminohippurate clearances over 10-17 days. Administration of either bGH (100-200 micrograms/day) or hIGF-I (200 micrograms/day) to rats with normal renal mass increased inulin and p-aminohippurate clearances compared with those measured in animals that received vehicle. Filtration fractions were not affected by either bGH or hIGF-I. Inulin clearance was decreased to approximately 17% of normal 1 day after reduction of renal mass in rats. Over the next 3 days insulin clearance increased significantly in rats with reduced renal mass that were administered vehicle. No further enhancement occurred during the next 7 days. Neither bGH nor hIGF-I affected inulin clearance in rats with reduced renal mass. We conclude that both GH and IGF-I enhance glomerular filtration rate when administered to rats with normal renal mass, but not when administered in the same quantities to rats in which renal functional mass is reduced. Glomerular filtration rate increases within 4 days of renal mass reduction independent of exogenous GH or IGF-I.

scholarly journals Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life

2004 ◽  
pp. 325-332 ◽  
Author(s):  
T Mahajan ◽  
A Crown ◽  
S Checkley ◽  
A Farmer ◽  
S Lightman
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
Rating Scales ◽  
Nottingham Health Profile ◽  
Psychiatric Evaluation ◽  
Gh Therapy ◽  
Gh Treatment ◽  
Psychiatric Interview ◽  
Atypical Depression

OBJECTIVE: Some growth hormone deficient adults (GHDAs) have an impaired quality of life, which may improve with growth hormone (GH) treatment. The objective of our study was to make an in-depth psychiatric evaluation of patients with adult-onset (AO) and childhood-onset (CO) GH deficiency (GHD), and to assess the time course of changes in their quality of life and symptoms of depression in response to GH treatment. DESIGN: The study design was a 4-month, double-blind, cross-over, placebo-controlled trial of GH therapy. METHODS:We used a detailed psychiatric interview to characterise 25 patients with proven GHD at baseline. They were reassessed at monthly intervals during treatment with GH or placebo, using the Nottingham Health Profile and two well-recognised depression rating scales. RESULTS: 11/18 (61%) of the patients with AO-GHD, but 0/7 of the patients with CO-GHD, were found to have atypical depression at baseline. There were significant improvements in the depression rating scale scores after 2 months of GH therapy, with significant improvements in emotional reaction and social isolation scores from 1 month, and in energy levels and sleep disturbance from 2 and 3 months respectively. CONCLUSIONS: The results of our study confirm that a large proportion of GHDAs have unequivocal psychiatric morbidity, and suggest that a response to treatment can be seen after a short trial of GH therapy. We hypothesise that this rapid improvement of symptoms of atypical depression represents a direct central effect of GH therapy.

Sign in / Sign up

Export Citation Format

Share Document